Gustavo A. Rosario Benitez

Array ( [id] => 17200106 [patent_doc_number] => 20210340201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => IMMUNOTHERAPY TARGETING KRAS OR HER2 ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/270400 [patent_app_country] => US [patent_app_date] => 2019-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090485 [patent_doc_number] => 20200199229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => HUMANIZED OR CHIMERIC CD3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/544376 [patent_app_country] => US [patent_app_date] => 2019-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16544376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15993447 [patent_doc_number] => 20200172594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/530748 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466607 [patent_doc_number] => 12522640 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => IL2 agonists [patent_app_type] => utility [patent_app_number] => 17/262097 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 10 [patent_no_of_words] => 27380 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837738 [patent_doc_number] => 20220275043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => SOLUBLE MULTIMERIC IMMUNOGLOBULIN-SCAFFOLD BASED FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/257671 [patent_app_country] => US [patent_app_date] => 2019-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17257671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16743456 [patent_doc_number] => 10968431 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Adoptive transfer of CD8+ T cell clones derived from central memory cells [patent_app_type] => utility [patent_app_number] => 16/514813 [patent_app_country] => US [patent_app_date] => 2019-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 11153 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16514813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569161 [patent_doc_number] => 20210008167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => T CELL RECEPTOR FUSIONS AND CONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/508279 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16508279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460276 [patent_doc_number] => 20220073581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => ANTIBODIES COMPRISING A POLYPEPTIDE INSERTED IN FRAMEWORK 3 REGION [patent_app_type] => utility [patent_app_number] => 17/259090 [patent_app_country] => US [patent_app_date] => 2019-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082112 [patent_doc_number] => 20210277118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => COMPOSITIONS INCLUDING CD3 ANTIGEN BINDING FRAGMENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/254105 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41212 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454549 [patent_doc_number] => 20200040099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => Single chain binding molecules comprising N-terminal ABP [patent_app_type] => utility [patent_app_number] => 16/444144 [patent_app_country] => US [patent_app_date] => 2019-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16444144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267533 [patent_doc_number] => 20190382500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/439495 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85158 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16439495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214505 [patent_doc_number] => 20210347842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => COMPOSITIONS AND METHODS OF USE OF IL-10 AGENTS IN CONJUNCTION WITH CHIMERIC ANTIGEN RECEPTOR CELL THERAPY [patent_app_type] => utility [patent_app_number] => 15/733970 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214505 [patent_doc_number] => 20210347842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => COMPOSITIONS AND METHODS OF USE OF IL-10 AGENTS IN CONJUNCTION WITH CHIMERIC ANTIGEN RECEPTOR CELL THERAPY [patent_app_type] => utility [patent_app_number] => 15/733970 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948136 [patent_doc_number] => 20210206827 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-07-08 [patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/436110 [patent_app_country] => US [patent_app_date] => 2019-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948136 [patent_doc_number] => 20210206827 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2021-07-08 [patent_title] => COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/436110 [patent_app_country] => US [patent_app_date] => 2019-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16436110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15144997 [patent_doc_number] => 20190350976 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => Methods for handling biological drugs containing living cells [patent_app_type] => utility [patent_app_number] => 16/433659 [patent_app_country] => US [patent_app_date] => 2019-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038593 [patent_doc_number] => 20190330301 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/416907 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11066 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16416907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267507 [patent_doc_number] => 20190382487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => ANTIGEN BINDING CONSTRUCTS TO CD8 [patent_app_type] => utility [patent_app_number] => 16/417474 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22505 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267509 [patent_doc_number] => 20190382488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => ANTIGEN BINDING CONSTRUCTS TO CD8 [patent_app_type] => utility [patent_app_number] => 16/417482 [patent_app_country] => US [patent_app_date] => 2019-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16417482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15664069 [patent_doc_number] => 10596242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Transfected T-cells and T-cell receptors for use in immunotherapy against cancers [patent_app_type] => utility [patent_app_number] => 16/413939 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18647 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 156 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413939 [rel_patent_id] =>[rel_patent_doc_number] =>)